Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-Sized U.S. Hospitals

Published: Tuesday, May 01, 2012
Last Updated: Tuesday, May 01, 2012
Bookmark and Share
Collaboration creates distribution channel to previously underserved market segment.

QIAGEN N.V. announced that Cardinal Health has extended its portfolio of laboratory offerings to select U.S. hospitals to include QIAGEN automated laboratory systems and test kits for molecular diagnostics.

Cardinal Health, a leading health care services company, will distribute QIAGEN’s molecular diagnostics products to small and mid-sized hospitals in the U.S. that were previously not covered by QIAGEN’s own sales channels. According to the American Hospital Association, there are approximately 5,000 community hospitals in the U.S. To date, only about 10% of U.S. hospitals perform molecular diagnostics, but this share is expected to grow significantly providing substantial opportunities for growth. This collaboration is expected to create critical mass in distribution of molecular diagnostics to this market segment, thereby supporting the adoption of in-house molecular diagnostic testing among smaller U.S. hospitals. In general, molecular diagnostic tests can assist healthcare providers in detecting and profiling infectious diseases, cancers and patients’ genomic characteristics as a guide in treatment decisions. QIAGEN will support Cardinal Health customers with application and technical support resources.

“Cardinal Health is a highly respected health care services company and will be an excellent partner in offering hospitals the benefits of QIAGEN’s molecular technologies and systems for efficient laboratory workflow,” said Bernd Uder, Senior Vice President Global Sales of QIAGEN. “Many community hospitals seek to add molecular diagnostics to their patient care. However, the molecular diagnostics purchases of each community hospital are relatively small. Due to the large number and geographic dispersion of smaller hospitals, providing adequate coverage requires substantial critical mass in distribution resources. We are very excited about this relationship with Cardinal Health, as we expect to create access to QIAGEN products for hospitals of all sizes, where before they were primarily available to large hospitals and reference laboratories.”

Subject to regulatory approval in individual countries, QIAGEN’s global product offering for clinical laboratories addresses all application areas in molecular diagnostics from screening of asymptomatic patients to enable early treatment of diseases (Prevention), through testing of symptomatic patients to create a diagnosis (Profiling) and biomarker testing to guide treatment decisions (Personalized Healthcare), to rapid testing of patients without access to a laboratory infrastructure (Point of Need). This portfolio includes instruments to automate entire workflows from initial sample processing to the final result, as well as consumables that allow laboratories to run standardized or lab-developed tests. Molecular diagnostic products available in the U.S. include the Rotor-Gene Q MDx detection platform, which has been recently 510(k) cleared for in-vitro diagnostic use with a compatible artus Influenza A/B assay. Going forward, QIAGEN intends to obtain US FDA regulatory clearances and approvals for the entire modular QIAsymphony RGQ lab automation system, including the Rotor Gene Q series instruments, as well as a broad pipeline of corresponding tests currently under development.

“We know that there’s an increased desire among health care providers for cost-effective diagnostic tools that will facilitate better patient care,” said Chris Kerski, Senior Vice President and General Manager of Scientific Products at Cardinal Health. “We’re pleased to be able to work with QIAGEN to offer our customers the solutions they’re seeking in this new and rapidly changing market.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Hitachi High-Technologies, QIAGEN Collaborate
Hitachi High-Technologies Corporation and QIAGEN N.V. have entered into a long-term strategic collaboration involving initiatives to deliver important advances in molecular testing.
Thursday, June 18, 2015
QIAGEN Signs Ninth Master Collaboration Agreement for Companion Diagnostics
Master collaboration agreement is a framework for developing and commercializing QIAGEN companion diagnostics, paired with new or existing products.
Thursday, November 13, 2014
QIAGEN Licenses Blood Cancer Biomarkers
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers.
Saturday, July 26, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
FDA Approve QIAGEN PCR Kit For Use With Second Colorectal Cancer Drug
Clinically proven companion diagnostic gains U.S. approval to guide use of Amgen’s Vectibix® (panitumumab) in treatment of metastatic colorectal cancer.
Tuesday, May 27, 2014
QIAGEN Licences Biomarker for Blood Disorder from CeMM Vienna
Company plans to develop a molecular diagnostic test for the calreticulin mutations.
Thursday, April 10, 2014
QIAGEN Partners with Exosome Diagnostics
Molecular testing of biofluids promises unprecedented access to gene mutations, gene expression signatures and expression levels without costly, invasive tissue biopsies.
Wednesday, July 24, 2013
QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Companion Diagnostics
Several lymphoma-related biomarkers, including EZH2 Y641 gene mutations, rights acquired from British Columbia Cancer Agency.
Monday, June 10, 2013
Leading Tuberculosis Experts Explore Shortcomings in Current Immigrant TB Screening Policy
Improved immigration policy and replacement of century-old diagnostic tests have potential to significantly reduce cases of latent tuberculosis in the UK.
Tuesday, December 04, 2012
QIAGEN to Supply Molecular Screening Solutions to Increase Safety of Blood Donations in Brazil
The supply agreement covers molecular sample and assay technologies for a national PCR-based blood screening program for HIV and HCV.
Friday, June 05, 2009
QIAGEN to Supply Molecular Screening Solutions to Increase Safety of Blood Donations in Brazil
The agreement to supply molecular sample and assay technologies for a PCR-based blood screening program for HIV HCV in Brazil.
Friday, May 29, 2009
QIAGEN Tests Clinically Verified for the Monitoring of Swine Flu
German Bernhard Nocht Institute and Spanish Reference Laboratory detect infections with the H1N1 strain using QIAGEN’s artus influenza test.
Monday, May 04, 2009
QIAGEN and CNCI to Establish Cervical Cancer Screening Program in Kolkata
The initiative will be conducted over 5 years and is expected to reach 50,000 women.
Monday, April 27, 2009
EU Launches Project to Improve In-Vitro Diagnostics
QIAGEN led-consortium to develop standards for patient sample processing in order to facilitate the discovery and prediction of diseases.
Tuesday, January 13, 2009
Nobel Prize to HPV Researcher Highlights Importance of Cervical Cancer Screening and Prevention
The Nobel Prize-winning discovery of the causal link between human papillomavirus (HPV) and cervical cancer has spurred lifesaving prevention technologies – such as HPV testing and HPV vaccines - that are helping to eradicate cervical cancer globally.
Tuesday, October 07, 2008
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Crystal Clear Images Uncover Secrets of Hormone Receptors
NIH researchers gain better understanding of how neuropeptide hormones trigger chemical reactions in cells.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!